| [1] |
CHEN Shunqi, LIU Xinyi, ZENG Tao, LIU Mengyu, WANG Yuting, XIN Haibei, LI Yuanfeng, ZHOU Gangqiao#br#.
TM6SF1 affects the biological behavior of intrahepatic cholangiocarcinoma cells by inhibiting the KRAS-MEK-ERK signaling pathway
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(3): 261-270.
|
| [2] |
LIU Song, ZHANG Yonghui, WANG Qingdong, LI Long, YU Guangji.
Efficacy and safety of hepatic arterial infusion therapy sequential capecitabine and PD⁃1 inhibitor in the treatment of unresectable hilar cholangiocarcinoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(1): 90-95.
|
| [3] |
YANG Dalong, LU Haiming, ZHONG Jianhong, QI Lunan, CHEN Zushun, XIANG Bangde, LI Lequn, MA Liang.
Factors influencing the efficacy and safety of surgery for hilar cholangiocarcinoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(6): 644-649.
|
| [4] |
WANG Yunchao, YANG Xu, YANG Xiaobo, ZHAO Haitao.
Progress in targeted immunotherapy for advanced cholangiocarcinoma based on biological behavior
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(5): 469-476.
|
| [5] |
GUAN Canghai, LIU Lang, SHI Wujiang, WANG Jiangang, ZHONG Xiangyu, JIANG Xingming.
LncRNA SNHG20 regulates proliferation and invasion of cholangiocarcinoma through miR⁃520f⁃3p
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(4): 389-394.
|
| [6] |
XU Dongyun, WANG Juan, LI Ke, YU Guanzhen, YU Wenlong, XU Yongmao.
Expression of HOXC8 in hilar cholangiocarcinoma and its clinical significance
[J]. Chinese Journal of Oncology Prevention and Treatment, 2019, 11(2): 116-120.
|
